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ROLE OF JADE-1 IN DNA REPAIR IN RENAL CELL CARCINOMA 
LEILI, NIU 
ABSTRACT 
 Renal cell carcinoma (RCC) is a common and life-threatening cancer. Among 
RCCS, clear-cell renal cell carcinoma (ccRCC) is the most prevalent type and is highly 
malignant. ccRCC is initiated by loss of the von Hippel-Lindau tumor suppressor gene 
VHL. The pVHL protein binds and stabilzes the renal suppressor protein Jade-1 and 
exerts important growth suppressive activities through Jade-1. Since many solid tumors, 
like ccRCC, exhibit chromosomal instability and hence have defects in repair of DNA 
double-strand breaks (DSBs), we sought to determine the roles of Jade-1 and pVHL in 
these processes to elucidate mechanisms of cancer development. This study focused on 
the impact of pVHL on Jade-1 localization and expression levels in renal cancer cells by 
immunofluorescence microscopy and on Jade-1 expression levels by immunoblotting and 
qPCR when double-strand DNA damage is introduced using doxorubicin, 
neocarzinostatin or gamma irradiation.  Early results suggested but do not yet confirm 
that there are differences in Jade-1 localization and expression levels in response to DNA 
DSBs in renal cells and renal cancer cells with versus without wild-type pVHL.  More 
experiments are required to draw conclusions from these early data.   
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 1 
INTRODUCTION 
Renal cell carcinoma (RCC) is a neoplasm of renal tubular epithelium cells (1). 
RCC accounts for 80% to 85% of all primary malignant renal tumors (1). Each year 
65,000 RCC patients are diagnosed in the United States, and only 60% of patients survive 
(1). Smokers, obese and hypertensive people have a higher risk of suffering RCC (1). In 
addition, acquired polycystic disease, due to chronic dialysis, also increases the risk of 
RCC significantly (1). Therefore, understanding the mechanisms behind RCC is crucial 
for improving treatment. In morphology and molecular basis, RCC is categorized into 
several different types, among which the three most common types are clear cell renal 
cell carcinoma (ccRCC), papillary renal cell carcinoma, and chromophobe renal 
carcinoma (1). The most prevalent RCC is ccRCC which is associated with the von 
Hippel-Lindau gene (VHL) (1). The second most common RCC is papillary renal cell 
carcinoma that is closely related to MET proto-oncogene (1). Chromophobe renal 
carcinoma rarely occurs, and is due to losses of whole chromosomes (1). The present 
study focuses on ccRCC. 
One unique characteristic of ccRCC is a deficiency in expression of the VHL 
gene. Both inherited ccRCC and 70% sporadic ccRCC have biallelic VHL gene 
mutations (4). VHL gene is located in human chromosome 3p25-p26 (11). VHL protein 
(pVHL) is found in cytoplasm and nucleus of many human cells (5). Hergovich et al. 
found that pVHL colocalizes with and stabilizes microtubules in cells (5). The cellular 
cytoskeleton relies on microtubules composed with α/β-tubulin heterodimers (13). 
Microtubules are dynamic and function in cellular transportation, shape and division (13). 
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Researchers found that amino acids 95-123 on pVHL contribute to microtubule binding 
and stabilization in vivo (5). Disturbance on those amino acids may lead to easy 
detachment and cell spreading, which facilitates development of tumor cells. Thus, the 
amino acid sequence 95-123 is a frequent mutation spot in VHL-related tumors (5). In 
addition to ccRCC caused by VHL mutations, inactivation of the VHL gene can lead to 
ccRCC as well. A CpG-rich DNA (CpG island) in the 5’ regulatory area is normally not 
methylated in autosomal chromosomes (6). However, methylations on CpG islands can 
naturally occur on the X chromosome to achieve parental imprinting (6). In some renal 
carcinoma cells, the VHL gene contains no mutations but it is inactivated because of CpG 
island hypermethylation (6). 
The ccRCC is a type of well-vascularized tumor in which vascular endothelial 
growth factor (VEGF) is elevated (2). VEGF binds to endothelial cells specifically and 
can trigger angiogenesis and vascular permeability in vivo (2). Kim et al. proved that 
inhibition on VEGF resulted in tumor suppression (14). Tissues, including tumor tissues, 
require oxygen and nutrients in blood to thrive, so solid tumors need VEGF to promote 
angiogenesis to match with their huge nutrition demands. In ccRCC, VEGF transcription 
is up-regulated by transcription factor Sp1 under assistance of protein kinase C ζ (PKC ζ) 
(3). Sp1 binds directly to PKC ζ and its zinc finger area is phosphorylated by PKC ζ (3). 
When renal carcinoma cells are transformed to overexpress PKC ζ, Sp1-mediated VEGF 
transcription is activated (3). Therefore, activation of VEGF transcription in ccRCC 
depends on binding of Sp1 with PKC ζ and phosphorylation of the zinc finger of Sp1 by 
PKC ζ (3). This mechanism is shown in Figure 1(a). The elevated VEGF transcription 
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and inactive VHL gene in ccRCC draw attention to the link between VEGF and VHL. As 
a tumor suppressor gene, VHL was hypothesized to influence VEGF transcription in 
normal renal tubular epithelial cells to some extent. Soumitro et al. discovered that VEGF 
transcription was inhibited by pVHL when the wild-type VHL gene was introduced into 
renal carcinoma cells (3). pVHL competed directly with PKC ζ for Sp1 binding (3). With 
binding to pVHL, Sp1 cannot interact with PKC ζ, and thus Sp1-mediated VEGF 
transcription is suppressed. The mechanism is shown in Figure 1(b). 
Figure 1: Activation and Inhibition of VEGF Transcription. (a) Activation of VEGF 
transcription by Sp1 and PKC ζ. The ‘P’ in red star represents phosphorylation of SP1 by 
PKC ζ. (b) Inhibition of VEGF transcription by pVHL. The pVHL binds to Sp1, 
displacing PKC ζ.The above mechanism gives an explanation for the decreased pVHL 
and elevated VEGF transcription observed in ccRCC, suggesting that pVHL work as a 
tumor suppressor. To investigate the tumor suppressor role of pVHL further, a human 
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kidney library was screened with a VHL p30 probe to find proteins that potentially 
interact with pVHL(7). Through a yeast two-hybrid approach, a novel protein encoded 
from Jade-1 was discovered to bind strongly with pVHL. Jade-1 stands for gene of 
apoptosis and differentiation in epithelia (7). The Jade-1 protein has a short lifetime and 
western blot shows that Jade-1 protein appears in human liver, pancreas and heart, but 
mostly in kidney (7). Western blot analysis shows that the Jade-1 protein is mainly 
located in renal proximal tubule cells (7). The primary site for Jade-1 protein indicates a 
potential link between Jade-1 protein and ccRCC because proximal tubules are the initial 
location where ccRCC occurs (7). In proximal tubule cells, Jade-1 protein is found in the 
cytoplasm and nucleus like pVHL, which further suggests an interaction between pVHL 
and Jade-1 protein (7). The interaction between pVHL and Jade-1 protein was confirmed 
by the observation from Zhou et al. that transfected pVHL colocalized with endogenous 
Jade-1 protein in the nucleus and cytoplasm of renal cancer cells (7). 
Coimmunoprecipitation of Jade-1 protein and pVHL illustrated that the inter-
PHD (plant homeodomain) region and amino terminus of Jade-1 protein were responsible 
for its interaction with pVHL (7). After confirming the interaction between pVHL and 
Jade-1 protein, Zhou et al. were interested in impacts of pVHL on Jade-1 protein, so they 
compared Jade-1 protein level changes in western blots with and without pVHL 
introduced to renal cells. Renal cells with pVHL had a significant higher level of Jade-1 
protein 3 days after the transfection, compared to pVHL-deficiency cells. Because 
regulatory elements for the Jade-1 DNA sequence remained constant in both conditions, 
it was believed that pVHL did not influence transcription of Jade-1. Moreover, the 
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elevation on Jade-1 did not show up immediately but 3 days after instead, so pVHL 
mainly impacted on Jade-1 protein stabilization (7). Further studies showed that pVHL 
stabilized Jade-1 by elongating the half-life of Jade-1 protein (7). Therefore, Jade-1 is 
stabilized by and partnered with pVHL as a potential renal tumor suppressor. 
Later studies confirm the renal tumor suppressor role of Jade-1 in terms of two 
aspects: apoptosis inducement and Wnt/β-catenin signaling inhibition. Immortality of 
tumor cells is partially due to an escape from apoptosis, so apoptosis activation in tumor 
cells is one solution to suppress tumor growth. The anti-apoptotic protein Bcl-2 level is 
decreased by Jade-1, resulting in a 40%-50% increase in apoptosis (8). Besides, an 
activated apoptotic factor, caspase 3, was detected in renal cancer cells with stable Jade-1 
introduced (8). These results explained observations whereby Jade-1 suppressed renal 
tumor formation and growth in nude mice (8). The Wnt/β-catenin pathway regulates 
cellular interactions during embryonic periods (9). There are two types of Wnt/β-catenin 
pathways: canonical and non-canonical pathways, but β-catenin is only activated in the 
canonical pathway (9). Accumulated β-catenin inhibits cadherin adhesion and promotes 
epithelial-mesenchymal transition, both facilitating cancer progression (9). Therefore, 
Wnt/β-catenin signaling contributes to tumor growth, and patients with poor prognosis 
tend to have higher level of cytoplasmic β-catenin (9). Since Jade-1 was proved to 
suppress renal tumor growth, Chitalia et al. made a link between Jade-1 and Wnt/β-
catenin. Coimmunoprecipitation confirmed that Jade-1 indeed interacted with β-catenin 
(11). To suppress tumor growth, β-catenin has to be degraded. Ubiquitination is a 
common process to breakdown molecules in cell. Jade-1 possesses two PHD domains. 
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Proteins with PHD domains show E3 ubiquitin ligase activity, so Jade-1 works as a 
ubiquitin ligase for β-catenin, thus inhibiting Wnt signaling (11). Since previous studies 
demonstrated that pVHL stabilize Jade-1, Chitalia et al. hypothesized that pVHL was 
required for Jade-1 down regulations on the canonical Wnt signaling (11). In contrast to 
truncated pVHL forms that cannot stabilize Jade-1, intact pVHL inhibits Wnt signaling in 
a Jade-1-dependent manner (11). 
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SPECIFIC AIMS 
Exogenous and endogenous stimulation can trigger DNA damage, and that 
damage disturbs normal cellular functions. Normal cells have effective DNA repair 
mechanism to fix DNA damage. In contrast, many tumor cells have impaired DNA repair 
mechanisms, which allows more mutations that challenge prediction and treatment. 
Oxygen free radicals oxidize guanine to 8-OxoG in DNA, and 8-OxoG pairs with adenine 
like a normal guanine in DNA synthesis (16). Mammalian cells have 8-OxoG DNA 
glycosylase/AP lyase to get rid of 8-OxoG from DNA (16). The Human OGG1 gene, 
coding for 8-OxoG DNA glycosylase/AP lyase, is located on the same locus as the VHL 
gene (chromosome 3p25), and this locus was shown to be mutated in ccRCC cells (17). 
Therefore, DNA repair is compromised in ccRCC cells, and as a tumor suppressor gene 
in ccRCC, Jade-1 is hypothesized to regulate DNA repair mechanism.  
Wan et al. discovered that a long non-coding RNA (lncRNA)—lncRNA-
JADE—facilitated recruitment of transcription cofactors of Jade-1 after DNA damage 
(15). Although Wan et al. found that Jade-1 was elevated in human breast cancer cells 
after DNA damage, changes of Jade-1 in ccRCC cells are not clearly understood.  
Another aspect concerned in this study is the influence of pVHL on DNA 
double strand breakage (DSB). Several studies have revealed that pVHL is associated 
with gene stabilization. The pVHL positively regulates a tumor suppressor, p53. When 
severe DNA damage occurs, pVHL promotes p53 for apoptosis (18). Cells have two 
main mechanisms to deal with DSBs: homologous recombination (HR) and non-
homologous end joining (NHEJ). Homologous DNA sequences are used as templates for 
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precise repair in HR. NHEJ connects two DNA ends without a homologous DNA 
template, so NHEJ causes more errors. Ubiquitin chains function differently based on 
lysine residue they attach to. The K63-linked chains signal for DNA repair. Studies found 
that K63-SOCS1-mediated ubiquitination of pVHL facilitates HR (19), so pVHL 
stabilizes genes by providing them a relatively precise repair process. 
Based on previous studies, both Jade-1 and pVHL have close relationships with 
DNA repair pathways, so this study aims to find out the interactions between Jade-1 and 
pVHL in DSBs. This study specifically focuses on DSBs in ccRCC cells and embryonic 
kidney cells. 786-O is a renal carcinoma cell line that lack the VHL gene, so Jade-1 
cannot be stabilized. 293T is an embryonic renal cell line with pVHL, so Jade-1 can be 
stabilized. The difference in the presence of VHL gene allows me to test the hypothesis 
that after DSBs, the presence of pVHL influences Jade-1 transcription and expression. To 
test this hypothesis the following steps will be done: 
(1) Determine whether colocalization occurs between Jade-1 and DSB sites. 
(2) Observe changes in expression of Jade-1 protein via western blot. 
(3) Observe changes in transcription of Jade-1 via qPCR. 
(4) Analyze data and draw conclusions. 
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METHODS 
 
Cells and Media: 
Renal carcinoma cell line, 786-O, was obtained from Dr. Cohen’s laboratory. 
The 786-O LZ is the parental cell line without VHL gene. The 786-O HAVHL cell line is 
the parental 786-O cell line transfected by vector with VHL gene (from stocks in Dr. 
Cohen’s laboratory). The 786-O HAV0 cell line was parental 786-O cell line transfected 
with vector without VHL gene (from stocks in Dr. Cohen’s laboratory). All three 786-O 
cell lines were grown in Roswell Park Memorial Institute medium supplemented with L-
glutamine, 10% fetal bovine serum, and 1% penicillin-streptomycin. 
The human embryonic kidney cell line, 293T, was obtained from Dr. Cohen’s 
laboratory. 293T cells were grown in Dulbecco’s modified Eagle’s medium mixed with 
1% penicillin-streptomycin and 10% fetal bovine serum. 
All cell lines were incubated in a Forma Scientific CO2 Water Jacketed 
Incubator. The temperature was set at 37 Celsius degrees and CO2 level was 5%. Ionized 
water mixed with anti-bacteria solution was put inside incubator to keep the environment 
moist.   
Double-strand DNA damage: 
Neocarzinostatin was stored at concentration of 500 ng/ml (NCS, #N9161, 
SigmaAldrich). NCS was used to cause DSBs in western blot and qPCR experiments. For 
786-O cells growing in 1ml media, 0.4 μl NCS was added to make a final concentration 
of 200 ng/ml. For 293T cells growing in 1ml media, 1 μl NCS was added to make final 
concentration of 500 ng/ml. Doxorubicin (Dox) in dimethysulfoxide (DMSO) was stored 
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at concentration of 5 mg/ml (Dox, #S1208, Selleckchem). Dox was used to cause DSBs 
in immunofluorescent imaging experiments. For cells growing in 1ml media, the final 
concentration of Dox added was 200 ng/ml. The irradiation source belongs to Boston 
University School of Medicine. The irradiation source was cesium-137, and irradiation 
strength was set to be 4 gray of ionization (400 rads). After treatment, cells were 
collected at certain time points for immunofluorescent image, western blot, and qPCR.  
Cell Counting: 
To make sure each well of a 6 well plate contain 750×103 cells, a hemocytometer 
was applied every time when transferring cells to a 6-well plate. After trypsinzation and 
centrifugation, cells were resuspended in 1 ml media. One 50 μl diluted mixture was 
made at 5X or 10X, and 10 μl out of it was added to hemocytometer. Cells were counted 
under Olympus CK2 light microscope. Based on the concentration calculated from the 
hemocytometer, a portion of 4500×103 cells was diluted to 1200 μl. For each well, 200 μl 
mixture was added. To grow cells, 1.5ml media was added to each well. 700 μl media 
was removed to make the total volume to be 1 ml on the day when drugs were added.  
Immunofluorescent Imaging: 
Cells were seeded on 8 mm circular coverslips, in 6 well plates. When coverslips 
were fully confluent, cells were left untreated or treated with NCS, Dox, or irradiation, 
for the indicated times. For recovery experiments, media was aspirated from wells then 
washed once with appropriate media, and fresh media added back for appropriate times. 
Plates were removed from the incubator and media was removed. Cells were washed with 
cold 1X phosphate buffered saline (PBS).  The samples were fixed with 400 μl of 3.7% 
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paraformaldehyde in PBS, pH 7.4 for 15 min at room temperature. Fixed samples were 
washed twice with cold PBS. The samples were permeabilized with 400 μl of 0.25% 
Triton X-100 in PBS for 10 min at RT. Samples were washed with cold PBS three times, 
5 minutes each. Samples were blocked with 1% bovine serum albumin (BSA) in PBST 
(1X PBS, 0.05% Tween-20) for 30 minutes at room temperature. Samples were incubated 
overnight with 350 μl of diluted primary antibodies (xxx) with blocking buffer at 4°C. 
The dilutions for the antibodies were as follows: Jade-1 1:350, phosphorylation of H2Ax 
on its S139 site (γH2AX) 1:750, 4′, 6-diamidino-2-phenylindole (DAPI) 1:150. Samples 
were washed with cold PBS for 4 times, 5 minutes each time, then were incubated with 
250 μl of 1:1000 diluted fluorescein-linked secondary antibodies rhodamine red –X goat 
anti-mouse IgG (H+L) (Life Technologies, R6393) for γH2AX and Oregon Green 488 
for 1 hour at RT in the dark. Samples were washed again with cold PBS 4 times for 5 
minutes each time. The coverslips were carefully mounted with 6 μl of Vectashield 
mounting media (Vector Laboratories Cat. No. H-1200) containing DAPI on clean glass 
slides and sealed with clear nail polish. Slides were imaged with a Leica SP5 confocal 
microscope and stored in 4°C in the dark. 
Western Blot: 
1. Protein Extraction 
Media was removed from 6 well plate. Cells were washed with cold 1X PBS 
three times. Lysis buffer was made of 100X phenylmethylsulfonyl fluoride (PMSF), 
100X NaVO4, 100X NaF, 100X Leupeptin (LEU, from Sigma # 103476-89-7), 1000X 
dithiothreitol (DTT), 10X protease inhibitor cocktail solution (PI, from Thermo Scientific 
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#88666) dissolved in NP40, and 50 μl lysis buffer was added to each well. Cells were 
harvested into 1.5 ml centrifuge tubes and were vortexed every 2 minutes for total of 10 
minutes. Cells were then centrifuged in a cold room at the highest speed for 10 minutes. 
Supernatant were transferred into new 1.5 ml centrifuge tubes and labeled protein 
samples.   
2. Protein Quantification 
For each sample, 3, 1.5 ml centrifuge tubes and 3 UV cuvettes were prepared. 
1ml 1X Bradford solution (Thermofisher, # 23200) and 2 μl protein lysate were added to 
and mixed in each 1.5 ml centrifuge tube. 900 μl of the mixture in each centrifuge tube 
was added to one cuvette. Protein concentrations were quantified in spectrometer. Final 
protein concentration used for each sample was the average of 3 individual tests.    
3. Electrophoresis 
Lysate was mixed with Laemmli Sample Buffer (LSB) in a ratio of 6:1. Protein 
samples were boiled in water at 100°C for 5 minutes. Samples were centrifuged twice, 
and were vortexed in between. The loading volume was calculated based on protein 
concentration to load protein samples evenly (60 μg) on sodium docdecyl sulfate 
polyacrylamide gel (SDS-Pages). SDS-Pages gels were run in 100X 
trishydroxyethylaminomethane-glycine SDS Running Buffer (#BP-150, Boston 
Bioproducts). For each gel the voltage was 100V and time was 120 minutes. For 2 gels at 
the same time, current was 40mA, and time was 120 minutes. Gels were transferred onto 
membranes in 100X transfer buffer (#BP-190, Boston Bioproducts). The transfer voltage 
was 100V, and time was 75 minutes. 
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4. Immunostaining 
Each membrane was shaken in Ponceau S stain (#F19J101, Boston Bioproducts) 
for 2 minutes. Areas without bands were cut off. The membrane was washed in 0.1% 
PBST for 2 minutes. Membranes were blocked by 5% milk solution for 1 hour (instant 
nonfat dry milk in 0.1% PBST). After blocking, membrane was washed in 0.1% PBST 
for 2 minutes. Membranes were submerged in primary antibody solution overnight at 4 
C°. Jade-1 anti-serum (from Dr. Cohen’s Lab) and β actin antibody (Cell Signaling 
Technology, #4967) were diluted in 0.1% PBST in a ratio of 1:250 and 1:1000 
respectively. The next day the membranes were washed in 0.1% PBST for 10 minutes for 
3 times. Secondary antibodies were diluted in 1% milk solution in a ratio of 1:5000. 
Rabbit secondary antibody was for Jade-1 bands, and mouse secondary antibody was for 
β actin bands. Membranes were submerged in secondary antibody solution for 1 hour. 
Membranes were finally washed in 0.1% PBST for 10 minutes, 3 times. Membranes were 
submerged in ECL solution (Thermofisher, # 32106) and developed in a developer. 
Developed films were scanned into computer by using a scanner (Epson perfection V39). 
Densitometry was calculated by using ImageJ Fiji.   
qPCR: 
Cells in 6 well plates incubated at room temperature. RNAs were isolated by 
using Quick-RNA MiniPrep Kit following the manufacturer’s instructions (#R1055, 
Zymo Research). Concentrations of RNA samples were quantified in a Nanodrop 
spectrometer. RNA samples were mixed with 5X cDNA synthesis buffer, dNTPs, RNA 
primers-random, oligo dT, RT-enhancer, verso enzyme, and deionized water (Verso 
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cDNA Synthesis Kit, Thermoscientific). The ratios of components were based on the 
RNA concentration and followed the RNA reverse table in the appendix. The cDNAs 
were synthesized on an Applied BioSystems Veriti 96 Well Fast Thermal Cycler. The 
cDNAs were diluted with deionized water to 5 ng/μl or 10 ng/μl based on need. For 5 
ng/μl concentration, 9 μl cDNA was mixed with 1 μl Taqman assay and 10 μl master mix 
(Thermofisher, #4444554). Taqman assays are from Life Technologies: ACTB, 
Hs99999903_m1; GAPDH, Hs99999905_m1; J1S custom assay. For 10 ng/μl 
concentration, 5 μl cDNA was mixed with 1 μl Taqman assay, 10 μl master mix, and 4 μl 
deionized water. The cDNA samples were run in qPCR machine (Applied Biosystems 
7500 Fast Real-Time PCR System).  
Statistical Analysis: 
The western blot and qPCR data were analyzed with single factor ANOVA in 
Microsoft Excel.  
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RESULTS 
Immunofluorescent Imaging 
Since this study focused on the role of Jade-1 in double strand DNA damage, it 
was thought that locations of DSBs and Jade-1 signal could give a clue as to how they are 
related. Renal carcinoma cells (786-O LZ, HAVHL and HAV0) were treated with Dox or 
irradiation. There were 786-O control groups for both treatments. Since Dox is dissolved 
in DMSO, DMSO alone was added to negative control cells. For cells undergoing 
irradiation treatment, nothing was added to media, so its negative control was un-
irradiated cells. After treatments, cells were harvested and coated with Jade-1, DAPI, and 
γ-H2AX antibodies. The Jade-1 signal was stained in green. The DAPI detected nuclei 
were labeled in blue. The γ-H2AX detected DSBs were stained red. Colocalization 
between Jade-1 and γ-H2AX were quantified as colocalization coefficient. ImageJ Fiji 
was used to calculate colocalization coefficient.  
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Table 1: Colocalization coefficient between Jade-1 and γ-H2AX of 786-O cells. Dox 
treatment was 1-hour followed by 1-hour recovery time before cells are harvested. 
Irradiation allows 1-hour recovery time before cells are harvested. 786-O LZ and 
HAVHL Pool cells were treated with Dox or irradiation. 786-O HAV0 cells were treated 
with irradiation only. Fold changes represent differences between treated groups 
(irradiation and Dox treatments) and their control groups (untreated and DMSO 
treatments). LZ stands for 786-O LZ parental cells. HAVHL Pool stands for 786-O 
HAVHL Pool cells. HAV0 stands for 786-O HAV0 cells. 
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1. 786-O LZ Cell Line 
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Figure 2: 786-O LZ Immunofluorescent Images. 786-O LZ cells were treated with 
irradiation or Dox. Figure 2a and b are images of untreated cells, the control for 
irradiation treatment. The c and d are images of cells exposed to 4 gray irradiation. 
Irradiated 786-O LZ cells were allowed to recover for 1 hour before harvesting. The e 
and f are images of cells treated with DMSO, the negative control for Dox treatment. The 
g and h are images of cells treated with Dox. 786-O LZ cells were treated with 200ng 
Dox for 1 hour and allowed to recover for 1 hour before harvesting. Green represents 
Jade-1, red represents γ-H2AX targeting DSBs, and blue represents DAPI staining of 
nuclei. The magnification is 63X. The scale is 25 micron. 
In 786-O LZ cell line, Jade-1 is visible in both treatment and control groups 
(Figure 2). In the untreated group, Jade-1 appeared mainly in cytoplasm, leaving the 
nucleus empty. The Jade-1 signal appeared in cytoplasm of irradiation treated cells as 
well, but more Jade-1 signals showed up in nucleus, which made the nuclear boundary 
unclear. The intensity of Jade-1 was stronger in the irradiation treated cells compared to 
untreated cells. The DMSO and Dox group did not show as big a difference in 
distribution of Jade-1 signal. The Jade-1 signal distributed evenly in whole cells, but 
Jade-1 signal was stronger in Dox treated cells. The γ-H2AX antibody was detected in 
whole cells of both control and treatment groups, but was found more abundant and 
intense in treated cells. In merged images, orange dots represented colocalization of Jade-
1 and γ-H2AX (Figure 2a, c, e, g). The values of colocalization coefficient of both Dox 
and irradiation treatment groups were higher than untreated and DMSO groups. The 
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colocalization coefficient values were consistent with observations that there were more 
orange dots in nucleus in Dox and irradiation treatment groups than in control groups. 
Therefore, results indicated that DSBs occurred in naturally growing 786-O LZ cells but 
Dox and irradiation triggered more DSBs. Dox and irradiation caused an increase in Jade-
1 expression, especially in nucleus. Higher colocalization coefficient values suggested 
more abundant colocalizations of Jade-1 and γ-H2AX in treatment groups.  
2. 786-O HAVHL Pool Cell Line 
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Figure 3: 786-O HAVHL Pool Immunofluorescent Images. 786-O HAVHL Pool cells 
were treated with irradiation or Dox. Figure 3a and b are images of untreated cells, the 
control group for irradiation treatment. The c and d are images of cells exposed to 4 gray 
irradiation. Irradiated 786-O HAVHL Pool cells were allowed to recover for 1 hour 
before harvesting. The e and f are images of cells treated with DMSO, the negative 
control for Dox treatment. The g and h are images of cells treated with 200 ng Dox. 786-
O HAVHL Pool cells were treated with Dox for 1 hour and allowed to recover for 1 hour 
before harvesting. Green represents Jade-1, red represents γ-H2AX targeting DSBs, and 
blue represents DAPI staining of nuclei. The magnification is 63X. The scale is 25 
micron. 
Like the 786-O LZ cell line, the DSBs signal was visible in both treated and 
control groups, but the treatment groups had more abundant and stronger staining in the 
nucleus. The intensity of Jade-1 was similar between treatment and control groups by the 
naked eye. Another difference from 786-O LZ cell line was the location of Jade-1 in 786-
O HAVHL Pool cells. Unlike the 786-O LZ control groups where Jade-1 was mainly in 
cytoplasm, the 786-O HAVHL Pool control groups had Jade-1 more condensed in 
nucleus even though the nuclear boundary was not very clear. After treatment, Jade-1 
signals in cytoplasm were much dimmer. Although Dox and irradiation treatment groups 
had more abundant and stronger DSBs signals, their values of colocalization coefficient 
were smaller than those of untreated and DMSO control groups. These results suggested 
that Jade-1 in 786-O HAVHL Pool cells is distributed mostly in nucleus, and DSBs 
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caused by Dox and irradiation made the difference in distribution of Jade-1 more 
obvious. Orange spots in nuclei indicated colocalization of DSBs and Jade-1 in 786-O 
HAVHL Pool cells. Compared to control groups, lower colocalization coefficient values 
in Dox and irradiation groups revealed lower colocalization between Jade-1 and DSBs 
signals.   
3. 786-O HAV0 Cell Line 
 
 
 
 
 
 
 
 
 
Figure 4: 786-O HAV0 Immunofluorescent Images. 786-O HAV0 cells were treated 
with irradiation. Figure 4a and b are images of untreated cells, the control for irradiation 
treatment. The c and d are images of cells exposed to 4 gray irradiation. Irradiated 786-O 
HAV0 cells were allowed to recover for 1 hour before harvesting. Green represents Jade-
1, red represents γ-H2AX targeting DSBs, and blue represents DAPI staining of nuclei. 
The magnification is 63X. The scale is 25 micron. 
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786-O HAV0 cell line were treated with irradiation only. The Jade-1 signals are 
spread throughout in whole cells of the untreated group. After irradiation, 786-O HAV0 
cells had more Jade-1 signals in nucleus than cytoplasm, which made Jade-1 signals in 
cytoplasm look dimmer. Very few DSBs signals showed up in untreated group, and 
irradiation group had much brighter and abundant DSBs signals in nucleus. Although 
orange spots indicating co-localization showed up in both treated and control groups, 
more orange spots were observed in treated group. A higher colocalization coefficient 
value for the irradiation group confirmed this observation. These results revealed that 
untreated 786-O HAV0 cells had Jade-1 diffusing in whole cells, which was similar to 
786-O LZ cells in the DMSO control group. DSBs caused by irradiation changed the 
primary distribution of Jade-1 to the nuclei, and colocalization between DSBs and Jade-1 
were more abundant after irradiation.  A caveat about this series of immunofluorescence 
experiments is that they were only performed the one time shown here.   
Changes in Jade-1 Expression 
Although immunofluorescent images disclosed that Jade-1 appeared near DSBs, 
changes in Jade-1 expression level after DSBs were not understood. Thus, western blot 
was applied to 786-O (LZ), 786-O HAVHL, and 786-O HAV0. NCS was used to trigger 
DSBs in cells. To see a series of changes in Jade-1, cells were harvested 2 hours, 4 hours, 
8 hours, 16 hours, and 24 hours after NCS treatment. Cells were treated at different time 
point and were collected at the same time. Jade-1 densitometry values were normalized 
by β actin density values. Fold changes were calculated on the basis of control (cells 
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without NCS). Any value above 1 indicates an increase of Jade-1 expression, and any 
number smaller than 1 represents a reduction in expression (Table 2).   
 
Table 2: Densitometry fold change of Jade 1 western blot band: 786-O cells were 
treated with 200 ng NCS for 2, 4, 8, 16 and 24 hours before cells were harvested. Fold 
changes were averaged from 3 experiments.    
1. 786-O LZ Cell Line: 
Based on three separate experiments, Jade-1 level changes were consistent at 2-
hour, 8-hour and 16-hour (Figure 5). At 2-hour, Jade-1 protein level had a fold increase 
of 1.978, but it dropped at 8-hour, which only had a fold increase of 1.571. Then there 
was an over 3-fold change at 16-hour. At 24-hour, Jade-1 protein level tended to decrease 
but was still higher than the untreated group. ANOVA p value of 0.015 indicated that 
Jade-1 level increased as NCS treatment length increased from 0 to 24 hours. 
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Figure 5: 786-O LZ Jade-1 expression changes as a function of time after NCS 
treatment. 786-O LZ cells were treated with 200 ng NCS for 2, 4, 8, 16 and 24 hours 
before cells were harvested. Figure 5a shows western blot bands. Top image is Jade-1 and 
the bottom image is β actin. UNTD refers to untreated cells. Band of Jade-1 is indicated 
with a red arrow. Figure 5b shows the average values of fold changes with standard 
deviations and ANOVA results. Standard deviation values are shown in Table 2. 
2. 786-O HAVHL Pool Cell Line: 
Between treatment lengths of 2 to 24 hours, the general trend of Jade-1 level was 
decreasing. Jade-1 had an average 6.5% increase at 2-hour treatment length, with a small 
standard deviation of 0.1. When NCS treatment length was above 2 hours, Jade-1 levels 
were lower than untreated group. Although standard deviations were large, the amount of 
reduction in Jade-1 became larger as NCS treatment length increased from 2 to 16 hours. 
After 24 hours of NCS treatment, Jade-1 in all three experiments showed signs of 
increase but varied widely. ANOVA results indicated that there was no significant 
change in Jade-1 protein level as NCS treatment length increased from 0 to 24 hours. 
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Figure 6: 786-O HAVHL Pool changes as a function of time after NCS treatment. 
786-O LZ cells were treated with 200 ng NCS for 2, 4, 8, 16 and 24 hours before cells 
were harvested. Figure 6a shows western blot bands. Top image is Jade-1 and the bottom 
image is β actin. UNTD refers to untreated cells. Band of Jade-1 is indicated with a red 
arrow. Figure 6b shows the average values of fold changes with standard deviations and 
ANOVA results. Standard deviation values are shown in Table 2. 
 27 
Changes on Jade-1 mRNA level 
Western blot revealed changes in Jade-1 protein expression, but changes in 
message levels were unknown. Therefore, qPCR was used to detect changes in Jade-1 
mRNA. Two 786-O cell lines (786-O LZ, 786-O HAV0) and one embryonic kidney cell 
line, 293T, were tested to investigate their differences in Jade-1 message. NCS was used 
to introduce DSBs to cells. The NCS treatment length was set to be 2, 4, 8, and 24 hours. 
Cells were treated at different time point and were collected at the same time. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was chosen as an endogenous 
control. Glyceraldehyde 3-phosphate dehydrogenase GAPDH is a housekeeping gene, so 
the level of GAPDH indicates the amount of genetic materials in sample. Cycle numbers 
of Jade-1 were normalized to GAPDH to avoid changes introduced by human errors 
during pipetting. Then normalized cycle numbers of Jade-1 in treatment groups were 
compared to control groups to get values of fold change. The control group was 
considered as the baseline and set to be 1. An increase in Jade-1 mRNA has a value of 
fold change above 1, and a decline has a value of fold change below 1. 
1. 786-O LZ Cell Line: 
4-hour NCS treatment did not increase Jade-1 mRNA level (Figure 7a). After 8 
hours of NCS treatment, there was a nearly 2.4 average fold increase in Jade-1 mRNA 
level, but a large standard deviation suggested a big variation in data. At the 24-hour 
NCS treatment time, an average fold increase of 1.4 was observed. However, the p values 
for all time points were greater than 0.05, so fold changes observed were not significant 
between the control and NCS treatment groups. ANOVA p value was greater than 0.05, 
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suggesting that Jade-1 mRNA did not change as NCS treatment time increased from 0 to 
24 hours. 
2. 786-O HAV0 Cell Line: 
After 4-hour NCS treatment, Jade-1 mRNA levels had an average 1.361 fold 
increase with a standard deviation of 0.49 (Figure 7b). Then, Jade-1 mRNA level dropped 
to 0.693 fold at 8-hour NCS treatment time, and data from three experiments did not vary 
too much at this time point (standard deviation of 0.14). After 24 hours of NCS treatment, 
Jade-1 mRNA level increased back to almost the same as 4-hour time point, but it had a 
big standard deviation value of 0.76. ANOVA was greater than 0.05, suggesting that 
Jade-1 mRNA did not change as NCS treatment length increased from 0 to 24 hours. 
3. 786-O HAVHL Pool Cell Line: 
In general, NCS treatment caused moderate reductions in Jade-1 mRNA level 
(Figure 7c). At 4-hour NCS treatment time, Jade-1 mRNA declined to 0.79 compared to 
untreated group. The Jade-1 mRNA level at 8-hour time point (fold change of 0.83) was 
close to 4-hour. After 24 hours of NCS treatment, Jade-1 mRNA level rose back to the 
level of untreated group. The standard deviation at 8-hour time point was as small as 
0.06, which showed the consistency of data from three experiments. ANOVA p value 
was 0.017, suggesting that Jade-1 mRNA decreased significantly as NCS treatment 
length increased from 0 to 24 hours.  
293T Cell Line: 
There was a huge variation at 4-hour (Figure 7, Table 3). Three out of four 
separate experiments had levels of Jade-1 mRNA close to control group, while one 
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experiment had an obvious drop as large as almost 48.3% (fold change of 0.518). When 
treatment length increased to 8 hours, level of Jade-1 mRNA kept decreasing. The 
average fold change at 8-hour was 0.684 with a small standard deviation of 0.135. At 24-
hour treatment length, levels of Jade-1 mRNA dropped to the lowest, although the data 
varied. ANOVA p value of 0.023 indicated that Jade-1 mRNA level decreased while 
NCS treatment length increased from 0 to 24 hours. 
Average fold changes of Jade-1 mRNA level in 786-O LZ, 786-O HAV0fold 
change values and standard deviations are shown in Table 3: Jade-1 mRNA Fold 
Change—LZ, Jade-1 mRNA Fold Change—HAV0, Jade-1 mRNA Fold Change—
HAVHL Pool, and Jade-1 mRNA Fold Change—293T.  
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Figure 7: Jade-1 mRNA level changes as a function of time after NCS treatment. 
786-O cells were treated with 200 ng NCS for 4, 8, 24 hours before cells were harvested. 
293T cells were treated with 500 ng NCS for 4, 6, 24 hours before cells were harvested. 
Isolated RNA samples were transcripted back to cDNA. The cycle number of Jade-1 
cDNA replication inversely shows the amount of Jade-1 mRNA. Figure 7a represents 
changes of Jade-1 mRNA level in 786-O LZ cell line with ANOVA results. Figure 7b 
represents changes of Jade-1 mRNA level in 786-O HAV0 cell line ANOVA results. 
Figure 7c represents changes of Jade-1 mRNA level in 786-O HAVHL Pool cell line 
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ANOVA results. Figure 7d represents changes of Jade-1 mRNA level in 293T cell line 
ANOVA results. 
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Table 3: Jade-1 mRNA fold change and standard deviation after NCS treatment. 
786-O cells were treated with 200 ng NCS for 4, 8, 24 hours. 293T cells were treated 
with 500 ng NCS for 4, 6, 24 hours before cells were harvested. Isolated RNA samples 
were transcripted back to cDNA. The cycle number of Jade-1 cDNA replication inversely 
shows the amount of Jade-1 mRNA. 
 
         In summary, these experiments support the idea that, in the absence of wild-type 
pVHL, induction of DSBs increases Jade-1 protein, which is supported by a possible 
increase or no change in Jade-1 message in these cells and increased colocalization of 
Jade-1 at H2AX-positive foci.  Surprisingly, in the presence of wild-type pVHL, Jade-1 
levels did not increase at the protein level and even decreased at the message level, and 
no increase in colocalization with DSBs was observed.   
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DISCUSSION 
Zhou et al. found colocalization of Jade-1 and VHL in the 786-O parental cell 
line, which supported their hypothesis about Jade-1 and VHL interactions. The goal of 
this study was to find functions of Jade-1 in DSBs, and it was thought that tests on 
colocalizations between Jade-1 and DSBs could give direct clues about their interactions. 
The two main aspects concerned in immunofluorescent imaging were the location of 
Jade-1 and its colocalizations with DSB sites. In 786-O LZ and 786-O HAV0 cells, Jade-
1 diffused more in cytoplasm, with some speckles in the nucleus. This finding is 
consistent with the results from Zhou et al.. The similarity in Jade-1 distribution between 
786-O LZ and 786-O HAV0 cells were expected because the 786-O HAV0 cell line 
served as a negative control. After DSBs were introduced by Dox and irradiation, Jade-1 
appeared to accumulate in nucleus in 786-O LZ and HAV0 cells. This result suggested 
that Jade-1 was involved in DSBs in VHL-deficient cells, and this result was consistent 
with an observation that 786-O LZ and 786-O HAV0 had increased colocalization 
coefficient values after DSBs.  
Besides the parental cell line, 786-O HAVHL Pool cells were tested for 
colocalization of Jade-1 and DSBs in this study. In contrast to 786-O parental cell line, 
786-O HAVHL Pool cells had Jade-1 enriched in nucleus before any DNA damage. This 
result suggested that pVHL might facilitate Jade-1 interactions with DSBs that occurred 
in nucleus as well. However, colocalization between Jade-1 and DSB sites was 
inconsistent with this hypothesis. Although DSBs in 786-O HAVHL Pool cells recruited 
Jade-1 into nucleus the same as in the parental cell line, the colocalization coefficient 
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value was essentially unchanged after DSBs were introduced. However, compared to an 
elevation as large as 70% in 786-O LZ and 786-O HAV0 cells, a <20% reduction of 
colocalization coefficient value in 786-O HAVHL Pool cells was not large enough to be 
considered a substantial difference. Based on this one experiment, the result indicated 
that pVHL did not facilitate the recruitment of Jade-1 in DSB sites.  
After knowing the locations of Jade-1, how DSBs made changes to Jade-1 was 
not understood. This study investigated this topic from two aspects: at the protein level 
and at the mRNA level. In this study, it was shown that parental cell line (786-O LZ) had 
an increasing trend in Jade-1 level, reaching a maximum at 16 hours after NCS treatment. 
The qPCR data revealed that Jade-1 mRNA level of 786-O LZ cells did not change as 
NCS treatment length increased. 786-O HAV0 had unchanged Jade-1 mRNA level as 
well as NCS treatment length increased, which is consistent with our expectation on 786-
O HAV0 as a negative control. Based on western blot and qPCR results, DSBs induced 
Jade-1 at the protein level but did not affect Jade-1 mRNA in renal cancer cells. The 
DSBs resulted in different consequences in breast cancer, another cancer related to Jade-
1. In breast cancer, Wan et al. found that Jade-1 was induced both at the protein level and 
transcriptionally (15). This comparison suggests that breast and renal cancers may have 
distinct mechanisms although Jade-1 is involved in both of them. 
To determine impacts of pVHL on Jade-1, 786-O LZ was compared to 786-O 
HAVHL Pool cells (Figure 8a and b). Previous studies showed that pVHL introduction 
promoted Jade-1 in 786-O cell line (11), but this study suggested a possibility that DSBs 
caused no change in Jade-1 level over time in the presence of wild-type pVHL. This 
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result revealed that without pVHL, Jade-1 seemed to be elevated by DSBs. With presence 
of pVHL, Jade-1 seemed to be kept the same level over time. One possible explanation is 
that with pVHL stabilization effects, there are sufficient Jade-1 proteins diffusing in 
VHL-transfected cells, so DSBs does not cause any changes. The true mechanism is still 
unclear. In terms of message, Jade-1 mRNA level in 786-O LZ cells was considered 
stable as NCS treatment length increased. However, cells with pVHL showed a 
decreasing trend in Jade-1 mRNA level as NCS treatment length increased.   
To investigate how Jade-1 behaved differently in healthy and tumorous renal 
cells, qPCR experiments were conducted on embryonic renal cell line (293T). Different 
from 786-O LZ, 293T cells had a reduction in Jade-1 mRNA level after DSBs (Figure 
8c). However, western blot results from a colleague showed that DSBs triggered the same 
Jade-1 protein accumulation in 293T cells as on 786-O LZ cells. This finding indicates 
that both cancer and healthy cells are able to increase Jade-1 at the protein level to deal 
with DSBs. Since 293T cells are embryonic renal cells with wild-type VHL gene, Jade-1 
protein is able to stay stable longer in 293T cells. Thus, it is possible that Jade-1 mRNA 
is down-regulated to prevent apoptotic effects of Jade-1 as a tumor suppressor. 
Surprisingly, 786-O HAVHL Pool cells also had a decreasing trend in Jade-1 mRNA 
level. This comparison indicates that pVHL probably functions similarly in both renal 
cancer cells and embryonic kidney cells. There might be a subtle increase in Jade-1 
protein level in 786-O HAVHL Pool, and it is the reason why we observed a down 
regulation of Jade-1 mRNA.  
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Figure 8: Comparison Among Cell Lines. The (a) represents average fold change of 
Jade-1 protein after NCS treatment. 786-O cells were treated with 200 ng NCS at 2, 4, 8, 
16, 24 hours before harvested. The (b) represents average fold change of Jade-1 mRNA 
after NCS treatment. 786-O cells were treated with 200 ng NCS at 2, 4, 8, 16, 24 hours 
before harvested. The (c) represents average fold change of Jade-1 mRNA after NCS 
treatment. 786-O cells were treated with 200 ng NCS at 4, 8, 24 hours before harvested. 
293T cells were treated with 500 ng NCS at 4, 8, 24 hours before harvested. LZ stands 
for 786-O LZ cell line. HAVHL Pool stands for 786-O HAVHL Pool cell line. 293 stands 
for 293T cell line. 
There are four aspects that might compromise results of this study. In some 
immunofluorescent images, the sizes of cell populations are too small. Characteristics of 
a whole cell line cannot be represented well from few cells, so more repeats need to be 
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finished in the future. Secondly, the Jade-1 band in western blots is too close to other 
nonspecific bands. Besides, a scanned copy of western blot film is more intense than it 
appears, so blurry boundaries of adjacent bands merge together sometimes. These factors 
introduced errors to densitometry analysis. To minimize negative effects caused by these 
errors, lower percent SDS-PAGE gel can be applied to make band space wider. Also, 
more specific Jade-1 antibody can eliminate distractions from nonspecific bands. The 
qPCR results are influenced by selections on endogenous controls. Although GAPDH 
mRNA level was very stable in 293T cell line, it varied a lot in 786-O cell lines, 
especially parental cell line. The β actin endogenous control was examined on as well, 
but GAPDH performed better in both 786-O and 293T cell lines. A better endogenous 
control is needed to reflect mRNA level more precisely. Limited experiment repeats also 
introduce uncertainty to this study. Almost all experiments were repeated only three 
times, and many data had very large standard deviations. To consolidate results, more 
repeats are needed in the future. 
One surprising result of this study is that colocalization between Jade-1 and 
DSBs is not promoted by pVHL. The increased colocalization coefficient value in 786-O 
LZ cells after DNA damages suggests that Jade-1 is indeed involved in DNA repair 
process, but this one experiment shows that Jade-1 may not rely on pVHL in this process. 
How Jade-1 functions in DSBs is not clearly understood, and more studies are needed in 
this field. 
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